€39 Million Raised to Progress Alport Syndrome Treatment

€39 million was raised by ENYO Pharma during a late-stage investment round to progress the development of Vonafexor, a therapy designed to treat Alport syndrome.  

Alport syndrome is a hereditary disorder associated with eye irregularities, renal problems, and hearing loss. 

Co-headed by OrbiMed and Morningside Ventures, the funding will aid the stage two Alpestria-1 research and additional studies for Vonafexor during the first six months of 2026. 

Furthermore, the financing will aid in the ongoing analysis of the treatment for additional renal conditions, such as autosomal dominant polycystic kidney disease. 

Dr Jack Vonderscher, the head executive of ENYO Pharma, stated, “There are huge unmet needs in many kidney diseases with fibrosis or inflammatory components. These patients almost invariably progress to end-stage kidney disease despite current therapies.” 

Vonderscher went on to comment, “The results already obtained with Vonafexor, our highly differentiated anti-inflammatory and fibrolytic lead compound, in patients with moderate kidney impairment and several preclinical protocols make us confident that it will greatly benefit those patients with rare kidney diseases like Alport syndrome.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.